Scanned and scattered proton beams showed similar tumor killing in Ewing sarcoma models
Scanned and scattered clinical proton beams produced similar Ewing sarcoma cell survival despite higher oxidative stress signals after scanned delivery.
Tag
Protons
Aperture-enhanced proton radiosurgery reduced normal brain dose for cerebral arteriovenous malformations
Aperture-enhanced proton stereotactic radiosurgery reduced normal brain dose compared with photon plans in most cerebral arteriovenous malformation cases.
Deep learning stopping power maps supported magnetic resonance-only proton planning for brain tumors
Synthetic stopping power maps showed small target dose differences, but residual range and low-dose gamma errors still require further validation.
Direct cord robust optimization preserved target coverage near the spinal cord
In ten paraspinal chordoma plans, direct cord robust optimization improved coverage and robustness while maintaining acceptable spinal cord doses.
Large target and heart volumes predicted replanning during proton therapy for thoracic cancer
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
Monte Carlo simulations identified depth-specific settings for proton minibeam radiation therapy
Simulated proton minibeams preserved spatial fractionation and target homogeneity for targets up to 20 centimetres with depth-adapted beam widths and spacing.
Hypofractionated proton reirradiation showed similar survival to photons in recurrent glioblastoma
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Conventional fractionation substantially reduced gastrointestinal motility–driven interplay in pancreatic proton therapy.
Gastrointestinal motility reduced single-fraction target coverage and broadened organ-at-risk dose ranges, while conventional fractionation substantially attenuated the interplay effect.
Proton therapy timing was not independently associated with worse rhabdomyosarcoma outcomes
Four-year overall survival was 81.2%, and starting proton therapy at week 14 or later was not independently associated with worse outcomes.
Respiratory gating limited accumulated motion-related dose errors in proton therapy for hepatocellular carcinoma
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.
Hybrid respiratory gating mitigated interplay in spot-scanning proton therapy
Hybrid phase-amplitude gating restored dose agreement during regular motion, while irregular breathing increased treatment time and produced inconsistent accuracy.
Neural model compresses proton Monte Carlo phase-space data while preserving dose accuracy
The neural model reduced phase-space storage from 3 gigabytes to 600 kilobytes while maintaining at least 89.9% gamma passing at 1%/1 mm.
Early diffusion changes precede brain lesions after proton therapy for low-grade glioma
Regional diffusion changes distinguished patients who developed contrast-enhancing brain lesions as early as six months after proton therapy.
Ultrahigh dose-rate protons reduce hydrogen peroxide yield in water
Hydrogen peroxide production decreased as proton dose rate increased, with Geant4-DNA simulations reproducing the oxygen-dependent experimental trend.
Neutron background limits prompt-gamma range verification in carbon-ion therapy
Prompt-gamma profiles tracked beam range, but stronger neutron backgrounds reduced retrieval precision for carbon ions under clinically relevant conditions.